Takeda's $4 Billion Psoriasis Bet Just Dropped Receipts

These "hard-to-treat" sites are a huge source of frustration for patients. You might have relatively little psoriasis on your body overall, but if it's covering your palms, you can't grip a coffee cup without pain. Standard severity scores often miss these patients entirely, classifying them as "mild" while they're miserable.

Zasocitinib delivered strong results in exactly these tough spots. For palms and soles, the clear/almost clear rate was 69 to 71%. And nail psoriasis showed statistically significant improvement as well, with responses holding steady through week 24.

These aren't secondary afterthoughts. For many patients, clearing these specific areas would be life-changing.

The Deucravacitinib Showdown

Now for the part BMS probably isn't thrilled about.

Both zasocitinib and BMS's deucravacitinib (brand name Sotyktu) belong to the same drug class: selective TYK2 inhibitors. Think of TYK2 as one member of the JAK family of enzymes that drives inflammation. Older JAK inhibitors blocked multiple family members at once, which worked but caused side effects like anemia and infections. The newer TYK2 approach targets just one family member, keeping efficacy high while (theoretically) reducing collateral damage.

Sotyktu got to market first, winning FDA approval in 2022. But its sales have been modest: $291 million globally in 2025. Uptake has lagged initial blockbuster expectations, partly because the efficacy, while solid, didn't blow doctors away.

Zasocitinib appears to be a sharper tool. In the head-to-head LATITUDE Atlas trial, more than 35% of zasocitinib patients achieved complete skin clearance at week 16, which was over 2.5 times the rate seen with deucravacitinib. Zasocitinib also showed statistical superiority for PASI 90 and completely clear skin (sPGA 0).

The molecular explanation is straightforward. Zasocitinib binds TYK2's regulatory domain with sub-picomolar affinity and boasts over one-million-fold selectivity for TYK2 versus other JAK enzymes. It was engineered to provide sustained, 24-hour pathway inhibition with once-daily dosing. Deucravacitinib hits the same target but with lower binding affinity and less sustained coverage over the dosing interval.

In pharma terms, zasocitinib is the sequel that learned from the original.

The $4 Billion Origin Story

Takeda didn't develop zasocitinib from scratch. The molecule was born at Nimbus Therapeutics, a small biotech that designed it using computational chemistry. In early 2023, Takeda paid $4 billion upfront to acquire the program, one of the splashiest deals in recent biotech history.

At the time, Takeda had Phase 2b data showing "biologic-level efficacy" from a pill: up to 68% of patients hit PASI 75 at week 12, with about a third reaching complete clearance on the highest dose. That was enough to justify writing a very large check.

Now, with Phase 3 data in hand, Takeda is projecting peak potential revenue of $3 billion to $6 billion across psoriasis and psoriatic arthritis. The company plans to file for FDA approval starting in its current fiscal year (which began April 2026).

What Could Go Wrong

Before anyone starts printing "best-in-class" on the label, a few caveats.

First, safety will be scrutinized closely. The reported adverse events (upper respiratory infections, nasopharyngitis, acne) look manageable so far, and Takeda says no new safety signals emerged. But regulators will want to see the full dataset, and the FDA has been cautious with the JAK/TYK2 class ever since cardiovascular concerns derailed broader JAK inhibitors.

Second, the market is complicated. Zasocitinib won't just compete with Sotyktu and Otezla. It has to convince doctors and patients that an oral pill is worth choosing over injectable biologics (IL-17 and IL-23 inhibitors) that already deliver extraordinary clearance rates. The convenience of a pill is a real advantage, but many biologic-experienced patients and their physicians may need convincing.

Third, pricing and access will matter enormously. BMS recently started offering Sotyktu at roughly $950 per month through a direct-to-consumer channel, more than 80% off list price. The oral TYK2 market is going to be a knife fight on access and affordability.

The Bottom Line

Takeda's zasocitinib just delivered Phase 3 data that look, by any reasonable measure, best-in-class among oral treatments for plaque psoriasis. The depth of skin clearance rivals injectable biologics. The head-to-head win over deucravacitinib is clean and convincing. And the hard-to-treat site data address a genuine, painful unmet need.

The $4 billion bet is looking smart. Now comes the harder part: turning clinical excellence into commercial dominance in a market where everyone is fighting for the same prescription pad.

The FDA Just Carpet-Bombed 25 Telehealth Companies Over Knockoff Ozempic

The FDA just hit 25 telehealth companies with warning letters for marketing compounded knockoffs of Ozempic and Mounjaro with bogus claims. It's the third enforcement wave in under a year, with over 100 total letters sent, and the real numbers on patient harm are alarming.